TABLE 4.
OS Estimates Stratified by Disease Extent and Genetic Alteration
| Solitary liver tumor | Multifocal liver disease | Nodal with or without distant metastases | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n | Events | Median OS, months (95% CI) | n | Events | Median OS, months (95% CI) | n | Events | Median OS, months (95% CI) | |
| All | 148 | 85 | 63.6 (55.6–84.9) | 86 | 56 | 30.0 (26.1–44.4) | 178 | 146 | 15.8 (13.3–19.0) |
| TP53 | |||||||||
| wt | 132 | 72 | 69.4 (58.6–87.1) | 71 | 44 | 40.6 (26.1–51.5) | 137 | 111 | 17.3 (14.2–21.4) |
| mut | 16 | 13 | 28.3 (12.3–NA) | 15 | 12 | 26.6 (21.8–NA) | 41 | 35 | 11.8 (9.9–26.7) |
| KRAS | |||||||||
| wt | 137 | 74 | 72.5 (58.6–87.9) | 80 | 50 | 30.7 (26.1–45) | 155 | 128 | 17.3 (13.7–20.6) |
| mut | 11 | 11 | 33.1 (17.8–NA) | 6 | 6 | 25.5 (17.9–NA) | 23 | 18 | 12.1 (5.9–24.1) |
| CDKN2A | |||||||||
| wt | 140 | 80 | 63.6 (55.6–84.9) | 76 | 47 | 32.8 (26.7–47.2) | 144 | 116 | 17.7 (14.2–23.9) |
| del | 8 | 5 | 74.8 (19.1–NA) | 10 | 9 | 19.3 (11.8–NA) | 34 | 30 | 11.9 (9.9–15.5) |
| Any genetic high risk | |||||||||
| wt | 121 | 64 | 72.5 (61–88.1) | 58 | 32 | 44.4 (26.8–67.7) | 100 | 81 | 18.7 (15.7–25.6) |
| alt | 27 | 21 | 47.6 (19.1–74.8) | 28 | 24 | 24.4 (17.9–32) | 78 | 65 | 12.1 (10.1–17.5) |
P values were adjusted for multiple comparisons within outcome using the false discovery rate correction. Abbreviations: alt, altered; ECOG, Eastern Cooperative Oncology Group; PS, performance status.